scholarly journals Non-traditional Risk Factors of Cardiovascular Disease and Coenzyme Q10 Therapy in Hemodialysis Patients

2021 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Elham Shahraki ◽  
Batool Shahraki ◽  
AliReza Dashipour
Keyword(s):  
Serum Albumin ◽  
Coenzyme Q10 ◽  
Antioxidant Properties ◽  
Serum Levels ◽  
Cardiovascular Complications ◽  
Hemodialysis Patients ◽  
Diabetic Patients ◽  
Beneficial Effects ◽  
Significant Difference ◽  
Coq10 Supplementation

Background: Inflammatory markers increase in end-stage renal disease (ESRD), especially in diabetic patients, and are positively correlated with cardiovascular mortality. Coenzyme Q10 (CoQ10), an agent with antioxidant properties, may be effective in reducing cardiovascular complications in hemodialysis patients. This study aimed to investigate the effects of CoQ10 supplementation on plasma C-reactive protein (CRP), homocysteine, and albumin in hemodialysis patients. Methods: Forty diabetic ESRD patients on hemodialysis for at least six months were evaluated in a double-blinded randomized clinical trial. The patients were randomly assigned to one of the two groups to receive either CoQ10 100 mg daily or placebo. In all patients, the serum levels of homocysteine, albumin, and CRP were measured before and after six months. Results: The mean age of the patients was 60.3 ± 9.1 years, and 57.5% of the participants were female. There was no statistical difference between the two groups at baseline. Furthermore, no significant difference was observed in serum albumin (P = 0.843), CRP (P = 0.214), and homocysteine (P = 0.21) at the end of the intervention between the groups. Conclusions: This study showed that in patients with ESRD, using CoQ10 supplementation has minimal beneficial effects on serum albumin, CRP, and homocysteine levels.

scholarly journals APOPTOSIS INDEX BETWEEN FEMALES AND MALES IN REGULAR HEMODIALYSIS

2016 ◽  
Vol 19 (3) ◽  
pp. 150
Author(s):  
Djoko Santoso
Keyword(s):  
Age Groups ◽  
Microtiter Plate ◽  
Hemodialysis Patients ◽  
Control Group ◽  
Diabetic Patients ◽  
Immunochemical Determination ◽  
Apoptosis Index ◽  
Significant Difference ◽  
And Control ◽  
Esrd Patients

Many reports have documented apoptosis index in hemodialysis patients, but to date, no single study has directly compared the apoptosis index of males to females. Data on mortality rate among hemodialytic patients in the hemodialysis center at the Department of Internal Medicine Dr Soetomo General Hospital, Surabaya, Indonesia show a high number predominated by female patients. Therefore, to answer the question of whether there is a gender difference in apoptosis index, the researcher studied leukocyte responses in male and female hemodialysis patients. The apoptosis index of the sample was measured by indirect immunoassay method. Cell lyses, followed by immunochemical determination of histone-complexed DNA fragments in a microtiter plate wells. The apoptosis quantization was obtained by determining the amount of colored product spectrophotometrically. One hundred and four non-diabetic subjects who received hemodialysis (HD), and 24 normal controls (NC), were evaluated. The apoptosis index in ESRD patients group and control group showed no significant difference (0.6172 vs 0.4008, p=0.114), neither did it vary in both sexes and age groups. When the sex factor was analyzed (after exclusion from the diabetic ESRD patients), females apoptosis index was significantly higher than that of the males (0.7325 vs 0.55175, p<0.05). In conclusion, apoptosis index in females among non-diabetic patients undergoing hemodialysis is higher than that occur in males and controls.

Pre-Dialysis Glycemic Control is An Independent Predictor of Mortality Intype Ii Diabetic Patients on Continuous Ambulatory Peritoneal Dialysis

1999 ◽  
Vol 19 (2_suppl) ◽  
pp. 179-183 ◽  
Author(s):  
Mai-Szu Wu ◽  
Chun-Chen Yu ◽  
Ching-Herng Wu ◽  
Jeng Yi Haung ◽  
Mei-Lin Leu ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Glycemic Control ◽  
Serum Albumin ◽  
Poor Glycemic Control ◽  
Control Group ◽  
Diabetic Patients ◽  
Type Ii ◽  
Good Glycemic Control ◽  
Cholesterol Levels ◽  
Significant Difference

Objective To evaluate the impact of pre-dialysis glycemic control on clinical outcomes for type II diabetic patients on continuous ambulatory peritoneal dialysis (CAPO). Materials and Methods One hundred and one type II diabetic patients receiving CAPO for at least 3 months were enrolled in a single institute. The patients were classified into two groups according to status of glycemic control. In the good glycemic control group, more than 50% of blood glucose determinations were within 3.3 11.0 mmol/L and glycosylated hemoglobin (HbA 1 C) levels were within 5% -10% at all times. In the poor glycemic control group, less than 50% of blood glucose determinations were within 3.3 -11.0 mmol/L, or HbA1C levels were above 10% at least 6 months before peritoneal dialysis was started. In addition to glycemic control status, pre-dialysis serum albumin, cholesterol levels, residual renal function, peritoneal membrane function, and modes of glycemic control were also recorded. Results The patients with good glycemic control had significantly better survival than those with poor glycemic control (p < 0.01). There was no significant difference in pre-dialysis morbidity between two groups. No significant differences were observed in patient survival between patients with serum albumin above 30 g/L and those with serum albumin under 30 g/L; between those with cholesterol levels above or below 5.2 mmol/L; and between those with different peritoneal membrane solute transport characteristics as evaluated by a peritoneal equilibration test (PET). Furthermore, there was no significant difference in survival between patients who controlled blood sugar by diet and those who controlled it by insulin. Cardiovascular disease and infection are the major causes of death in both groups. Although good glycemic control predicts better survival, it does not change the pattern of mortality in diabetic patients maintained on CAPO. Conclusions Glycemic control before starting dialysis is a predictor of survival for type II diabetic patients on CAPO. Patients with poor glycemic control predialysis are associated with increased morbidity and shortened survival.

The effects of concurrent Coenzyme Q10, L-carnitine supplementation in migraine prophylaxis: A randomized, placebo-controlled, double-blind trial

Cephalalgia ◽  
2019 ◽  
Vol 39 (5) ◽  
pp. 648-654 ◽  
Author(s):  
Parisa Hajihashemi ◽  
Gholamreza Askari ◽  
Fariborz Khorvash ◽  
Mohammad Reza Maracy ◽  
Mojgan Nourian
Keyword(s):  
Coenzyme Q10 ◽  
Metabolic Disorders ◽  
Primary Outcome ◽  
Serum Levels ◽  
Parallel Study ◽  
Double Blind ◽  
Beneficial Effects ◽  
Headache Diary ◽  
Combined Supplementation ◽  
To Receive

Purpose The present study aimed to determine the effects of combined supplementation of Coenzyme Q10 with L-carnitine on mitochondrial metabolic disorders marker and migraine symptoms among migraine patients. Methods A total of 56 men and women, between 20–40 years of age with migraine headache, participated in this randomized, double-blind, placebo-controlled, parallel study. The subjects were randomly assigned to receive either 30 mg/day Coenzyme Q10 and 500 mg/day L-carnitine at the same time and/or placebo tablets for 8 weeks. The measurements were completed at the beginning and end of the study. The primary outcome was severity of headache attacks. The secondary outcomes included duration, frequency of headache attacks, the headache diary results (HDR), and serum levels of lactate. Results A significant reduction was obtained in serum levels of lactate (−2.28 mg/dl, 95% CI: −3.65, −0.90; p = 0.002), severity (−3.03, 95% CI: −3.65, −2.40; p ≤ 0.001), duration (−7.67, 95% CI: −11.47, −3.90; p ≤ 0.001), frequency (−5.42, 95% CI: −7.31, −3.53; p ≤ 0.001) and HDR (−103.03, 95% CI: −145.76, −60.29; p ≤ 0.001) after 8 weeks. Conclusion This double-blind parallel study provides evidences supporting the beneficial effects of Coenzyme Q10 and L-carnitine supplements on serum levels of lactate and migraine symptoms. Trial registration IRCT20121216011763N21.

P1406A CASE-CONTROL STUDY ON RISK FACTORS OF CALCIPHYLAXIS: DATA FROM CHINESE HEMODIALYSIS PATIENTS

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Yuqiu Liu ◽  
Xiaotong Xie ◽  
Canlin Yang ◽  
Xin Yang ◽  
Xiao liang Zhang
Keyword(s):  
Risk Factors ◽  
Serum Albumin ◽  
Chinese Population ◽  
Warfarin Therapy ◽  
Hemodialysis Patients ◽  
Serum Phosphate ◽  
Serum Phosphate Level ◽  
Dialysis Patients ◽  
Increased Risk ◽  
Significant Difference

Abstract Background and Aims Calciphylaxis (CUA) is a rare but potentially fatal disease that is commonly occurred in dialysis patients. Since there is no data based on Chinese population, the study is aimed to investigate risk factors of CUA in Chinese hemodialysis patients. Method We retrospectively evaluated medical records of 20 hemodialysis patients who were newly diagnosed with CUA by skin biopsy admitted to Zhongda Hospital Southeast University from Oct.2017 to Dec.2018. Non-CUA dialysis patients with the same age and duration of dialysis were randomly selected as controls (Ratio=1:2). Results Most of CUA patients were male (80%) and elderly (55%), while 50% had a body mass index higher than 24. The mean time interval since start of dialysis to CUA diagnosis was 114.65±81.32 months, and the median time from appearance of skin lesion to diagnosis was 6 (2, 15) months. The incidence of hyperparathyroidism was higher in patients with CUA (80% vs 62.5%), but the differences of duration of elevated serum intact parathyroid hormone (iPTH) and its highest value were not significant compared with the controls. Warfarin therapy had no significant difference between two groups (15% vs 5%). Univariate logistic regression analysis indicated that male (OR 3.619, 95%CI 1.027-12.748), each 1 point increase in score of use of vitamin D and its analogues (OR 1.505, 1.029-2.201), each 1 mmol/L increase in corrected serum calcium level (OR 24.486, 1.570-381.873), each 1 mmol/L increase in serum phosphate level (OR 5.382, 1.767-16.389), each 1 pg/mL increase in iPTH level (OR 1.002, 1.000-1.003), each 1 g/L decline in serum albumin level (OR 1.181, 1.041-1.340), each 1 IU/L increase in serum alkaline phosphatase (ALP) level (OR 1.005, 1.000-1.009) and each 1 mg/L increase in hypersensitive c-reactive protein level (OR 1.029, 1.000-1.059) were significantly associated with CUA. Serum phosphate, albumin and ALP were still significant risk factors after multivariate analysis. Conclusion This is the first report of risk factors of CUA based on Chinese population. The results show that high levels of serum phosphate and ALP, low level of serum albumin are independent risk factors of CUA in Chinese hemodialysis patients. Unlike previous research from western countries, warfarin therapy didn’t show an increased risk in this study, propably because of the low exposure rate of it in China.

scholarly journals Serum IL-17, IL-23, and TGF-βLevels in Type 1 and Type 2 Diabetic Patients and Age-Matched Healthy Controls

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Azam Roohi ◽  
Mina Tabrizi ◽  
Farzaneh Abbasi ◽  
Asal Ataie-Jafari ◽  
Behrouz Nikbin ◽  
...  
Keyword(s):  
Serum Levels ◽  
Diabetic Patients ◽  
Low Grade ◽  
Healthy Controls ◽  
Type 2 Diabetic Patients ◽  
Significant Difference ◽  
Type 1 Diabetic Patients ◽  
Type 2 Diabetic

Type 1 diabetes is recognized as an autoimmune inflammatory disease and low grade inflammation is also observed in type 2 diabetic patients. Interleukin 17 (IL-17) is a new player in inflammation. Th17 cells, as the main source of IL-17, require transforming growth factorβ(TGF-β) and interleukin 23 (IL-23). The aim of this study was to investigate serum IL-17, IL-23 and TGF-βlevels in diabetic patients and controls. In this case-control study, serum levels of IL-17, IL-23, and TGF-βwere measured in 24 type 1 diabetic patients and 30 healthy controls using the ELISA method. Simultaneously, the same methodology was used to compare serum concentration of these three cytokines in 38 type 2 diabetic patients and 40 healthy controls. There was no significant difference between serum levels of IL-17 and IL-23 cytokines between cases and controls. However, TGF-βwas significantly lower in type 1 diabetic patients (P<0.001). Serum IL-17 and IL-23 levels demonstrate no association with type 1 and type 2 diabetes, but, in line with previous studies, TGF-βlevels were lower in type 1 diabetic patients.

scholarly journals Antioxidatant Effect of Atorvastatin and Rosuvastatin in Hyperlipidemic Patients: A Randomized Controlled Trial

2019 ◽  
Vol 14 (1) ◽  
pp. 54-58
Author(s):  
Samia Haque Tonu ◽  
Jasmine Fauzia Dewan ◽  
Nargis Akhter ◽  
Md Enamul Haque ◽  
Md Abdul Wahab
Keyword(s):  
Oxidative Stress ◽  
Lipid Profile ◽  
Serum Lipid ◽  
Controlled Trial ◽  
Armed Forces ◽  
Cardiovascular Complications ◽  
Serum Lipid Profile ◽  
Beneficial Effects ◽  
Significant Difference ◽  
Oxidative Stress Status

Introduction: Hyperlipidemia is a major risk for the development of atherosclerosis leading to cardiovascular complications. Atorvastatin and rosuvastatin are two widely used important members of the HMG-CoA reductase inhibitor (statins). The beneficial effects of statins on clinical events also involve lipid-independent mechanisms which include improvement of oxidative stress status. Objective: To compare the antioxidative effect of atorvastatin and rosuvastatin in patients with hyperlipidemia. Materials and Methods: A prospective randomized single-center analytic study was carried out in Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka from March 2016 to August 2017 on 52 hyperlipidemic patients. After randomization patients were assigned to atorvastatin 10 mg or rosuvastatin 5 mg daily for 8 weeks. Blood was collected at baseline and after the intervention to measure plasma malondialdehyde (MDA), erythrocyte reduced glutathione (GSH) (as biomarkers of oxidative stress) and serum lipid profile. Results: The baseline characteristics of patients treated with atorvastatin and rosuvastatin were almost identical. The level of plasma MDA in atorvastatin (1.35 ± 0.94 to 0.97± 0.64) and rosuvastatin (1.56±0.69 to 0.98±0.38) group was significantly reduced after intervention (28.15%, p<0.05 and 37.18%, p<0.001 respectively) but no statistically significant difference (p>0.05) was observed between the two statin-treated groups. Erythrocyte GSH level was increased after intervention in both atorvastatin (2.43±2.90 to 4.14 ± 4.87) group (70.37%, p<0.01) and rosuvastatin (2.76±3.80 to 8.36±12.93)  group (202.90%, p<0.01), which was statistically significant. No significant difference was observed between the two groups (p>0.05). Both atorvastatin and rosuvastatin significantly improved serum lipid profile. Conclusion: Both atorvastatin and rosuvastatin significantly improved oxidative stress status in hyperlipidemic patients but no significant change was observed between the two statin-treated groups. Journal of Armed Forces Medical College Bangladesh Vol.14(1) 2018: 54-58

scholarly journals SO044ALPHA LIPOIC ACID COMPARED TO SELENIUM IN MITOCHONDRIAL RESUSCITATION AND MI RNA-126 EXPRESSION IN HEMODIALYSIS PATIENTS

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Magdy ElSharkawy ◽  
Zainab Al Kasaby ◽  
Hosny A. Elewa ◽  
Maha Abdelrahman
Keyword(s):  
Oxidative Stress ◽  
Serum Level ◽  
Lipoic Acid ◽  
Demographic Data ◽  
Serum Levels ◽  
Cardiovascular Complications ◽  
Base Line ◽  
Coq10 Level ◽  
Mitochondrial Functions ◽  
Significant Difference

Abstract Background and Aims anti-oxidants may decrease the risk of cardiovascular complications (CVC) in HD patients. We aimed to study antioxidant effect of Alpha lipoic acid and selenium on oxidative stress, endothelial repair, and mitochondrial functions in HD patients by evaluating the serum level of reactive oxygen species (ROS), miRNA-126, and CoQ10. Method 60 individuals were enrolled and randomized into 3 groups, G1; 22 HD patients as control, G2; 20 HD patients received Selenium, and G3;18 HD patients received. Serum levels of ROS, CoQ10, and miRNA-126 were assessed at base line and after three months treatment for all patients. Results At baseline, all groups were matched regarding their demographic data and target parameters. After three months, in G1; the serum level of ROS increased significantly (P &lt; 0.05), CoQ10 didn't change significantly (P &gt; 0.05), while the fold expression of miRNA-126 decreased significantly (P &lt; 0.05). In G2,3; there were statistical significant changes in target parameters after the treatment, ROS level decreased significantly by 34%, and by 79%, CoQ10 mean levels increased significantly from 13.21 to 28.35, and from 13.46 to 36.43 ng/ml, mean fold expression of miRNA126, increased significantly by 6.94, and 10.54 folds, in Selenium and, Thiotacid groups respectively. The results showed that Thiotacid was better than Selenium in ROS level reduction, and CoQ10 level improvement, while no statistical significant difference between two drugs regarding miRNA126 level (P &gt; 0.05). Conclusion Selenium and, Thiotacid reduce oxidative stress and also they enhancing the endothelial repairing, and improve mitochondrial functions and thus may reduce risk of CVC.

scholarly journals Malondialdehyde, glutathione, glutathione peroxidase and homocysteine levels in type 2 diabetic patients with and without microalbuminuria

2005 ◽  
Vol 42 (2) ◽  
pp. 99-104 ◽  
Author(s):  
Gülsen Ozdemır ◽  
Meltem Ozden ◽  
Hale Maral ◽  
Sevinc Kuskay ◽  
Pinar Cetınalp ◽  
...  
Keyword(s):  
Glutathione Peroxidase ◽  
Vascular Disease ◽  
Healthy Subjects ◽  
Serum Levels ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Significant Difference ◽  
Total Homocysteine ◽  
Type 2 Diabetic

Background: High levels of homocysteine and oxidative stress are known to be associated with premature vascular disease in type 2 diabetes mellitus (DM). The aim of this study was to estimate homocysteine levels and oxidant-antioxidant status and to determine the relationship between them in type 2 diabetic patients with and without microalbuminuria. Methods: Fasting blood samples were obtained from 48 diabetic patients (17 with and 31 without microalbuminuria) and 20 healthy subjects. Serum total homocysteine (tHcy), plasma malondialdehyde (MDA) erythrocyte glutathione (GSH) and glutathione peroxidase (GPx) activity were measured in these patients and the results were compared with those of controls who were chosen among healthy subjects. Results: MDA levels were found to be significantly lower and GSH levels and GPx activities were found to be significantly higher in control subjects when compared with patients with and without microalbuminuria (MDA: P<0.0001, P<0.0001; GSH: P<0.0001, P<0.0001; GPx: P<0.0001, P<0.001, respectively). MDA levels were found to be significantly higher in patients with microalbuminuria compared with patients without microalbuminuria ( P<0.0001), while similarly GSH levels were found to be significantly lower in patients with microalbuminuria ( P<0.0001). Although there were no significant differences with respect to tHcy levels and GPx activities between the microalbuminuric and normoalbuminuric patients ( P>0.05), there was a significant difference with respect to tHcy levels between healthy controls and patients with microalbuminuria ( P<0.05). The serum levels of tHcy correlated best with plasma MDA and erythrocyte GSH concentrations in all diabetic patients ( r=0.549, P<0.0001; r=0.385, P<0.01). Conclusion: Decreased antioxidant levels, increased lipid peroxidation and increased tHcy levels were observed in patients with microalbuminuria. These changes may contribute to vascular disease, which is particularly prevalent in type 2 DM patients with microalbuminuria.

scholarly journals Tinzaparin Provides Lower Lipid Profiles in Maintenance Hemodialysis Patients: A Cross-Sectional Observational Study

2014 ◽  
Vol 2014 ◽  
pp. 1-9
Author(s):  
Ming-Hsien Tsai ◽  
Yu-Wei Fang ◽  
Jyh-Gang Leu
Keyword(s):  
Multivariate Analysis ◽  
Total Cholesterol ◽  
Univariate Analysis ◽  
Serum Triglyceride ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Maintenance Hemodialysis ◽  
Diabetic Patients ◽  
Significant Difference ◽  
The Impact

As a low-molecular-weight heparin, tinzaparin has effectively been used as an anticoagulant during hemodialysis sessions. However, the impact of different heparin types on dyslipidemia is still controversial. In our study, 434 chronic hemodialysis patients were evaluated. The mean age was 65 ± 13. Forty-eight patients (11%) and 386 patients (89%) were in the tinzaparin and unfractionated heparin (UFH) groups, respectively. Triglyceride had significant difference between the two groups (P=0.001) but total cholesterol, HDL, or LDL did not. In the univariate analysis, the triglyceride level was significantly associated with tinzaparin use [β: −39.9, 95% confidence interval (CI): −76.7 to −3.0], and this association remained following the multivariate analysis (β: −40.8, 95% CI: −75.1 to −6.5). The difference in serum total cholesterol level between tinzaparin and UFH became significant (β: −13, 95% CI: −24.5 to −1.56) after adjustment in the multivariate analysis. Moreover, in a subgroup analysis, male diabetic patients showed lower serum triglyceride levels with the use of tinzaparin, while older, nondiabetic, male patients showed significant advantages in total cholesterol levels with the use of tinzaparin. Based on our findings, tinzaparin shows a significant association with a lower lipid profile in patients with chronic hemodialysis when compared to UFH.

scholarly journals Coenzyme Q10 Supplementation for the Reduction of Oxidative Stress: Clinical Implications in the Treatment of Chronic Diseases

2020 ◽  
Vol 21 (21) ◽  
pp. 7870 ◽  
Author(s):  
Francisco Miguel Gutierrez-Mariscal ◽  
Antonio Pablo Arenas-de Larriva ◽  
Laura Limia-Perez ◽  
Juan Luis Romero-Cabrera ◽  
Elena Maria Yubero-Serrano ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Clinical Trials ◽  
Chronic Diseases ◽  
Coenzyme Q10 ◽  
Chronic Obstructive ◽  
Clinical Implications ◽  
Main Function ◽  
Alcoholic Fatty Liver ◽  
Beneficial Effects ◽  
Coq10 Supplementation

Apart from its main function in the mitochondria as a key element in electron transport, Coenzyme Q10 (CoQ10) has been described as having multiple functions, such as oxidant action in the generation of signals and the control of membrane structure and phospholipid and cellular redox status. Among these, the most relevant and most frequently studied function is the potent antioxidant capability of its coexistent redox forms. Different clinical trials have investigated the effect of CoQ10 supplementation and its ability to reduce oxidative stress. In this review, we focused on recent advances in CoQ10 supplementation, its role as an antioxidant, and the clinical implications that this entails in the treatment of chronic diseases, in particular cardiovascular diseases, kidney disease, chronic obstructive pulmonary disease, non-alcoholic fatty liver disease, and neurodegenerative diseases. As an antioxidant, CoQ10 has proved to be of potential use as a treatment in diseases in which oxidative stress is a hallmark, and beneficial effects of CoQ10 have been reported in the treatment of chronic diseases. However, it is crucial to reach a consensus on the optimal dose and the use of different formulations, which vary from ubiquinol or ubiquinone Ubisol-Q10 or Qter®, to new analogues such as MitoQ, before we can draw a clear conclusion about its clinical use. In addition, a major effort must be made to demonstrate its beneficial effects in clinical trials, with a view to making the implementation of CoQ10 possible in clinical practice.

Sign in / Sign up

Export Citation Format

Share Document